All In Biotech

Drug Trial Radar · NCT07911683

Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma

A Phase 2 Global, Single-Arm Study of BGB-B2033 Monotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Anti-PD-1/PD-L1 Therapies

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Mar 31, 2028

Study completion Sep 30, 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapies.

Conditions

  • Hepatocellular Cancer
  • Liver Cancer
  • Hepatocellular Carcinoma

Interventions

  • BGB-B2033Drug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Assessment (ORR) by Independent Review Committee AssessmentTime frame: Up to approximately 15 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.